Clinical Trial Update: A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Obexelimab for IgG4-related disease is active but not recruiting. The sponsor is Zenas BioPharma (USA), LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease

Drugs mentioned

• Obexelimab (obexelimab)

Snippet

Sponsor: Zenas BioPharma (USA), LLC | Conditions: IgG4 Related Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING